Gilles Lambert

Summary

Country: France

Publications

  1. ncbi request reprint Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c
    Philippe Costet
    INSERM, U539, CHU Hotel Dieu, 44000, Nantes, France
    J Biol Chem 281:6211-8. 2006
  2. ncbi request reprint Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects
    Gilles Lambert
    Faculte de Medecine, Universite de Nantes, UMR Phan 1280, Nantes, France Lipid Research Group, Heart Research Institute, Sydney, Australia Electronic address
    J Am Coll Cardiol 63:2365-73. 2014
  3. ncbi request reprint Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor
    Gilles Lambert
    Universite de Nantes, UFR de Medecine, Institut National de la Sante et de la Recherche Medicale, Unité 539, Centre Hospitalier Universitaire Hotel Dieu, 44093 Nantes, France
    Endocrinology 147:4985-95. 2006
  4. ncbi request reprint PCSK9: a promising therapeutic target for dyslipidemias?
    Gilles Lambert
    University of Nantes, Medical School, INSERM U539, CHU Hotel Dieu, 3 e Nord, 1 Place Alexis Ricordeau, F 44093 Nantes cedex 1, France
    Trends Endocrinol Metab 17:79-81. 2006
  5. ncbi request reprint Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells
    Florent Lalanne
    Institut National de la Santé et de la Recherche Médicale U539, Centre Hospitalier Universitaire, Hotel Dieu, Nantes, France
    J Lipid Res 46:1312-9. 2005
  6. ncbi request reprint Unravelling the functional significance of PCSK9
    Gilles Lambert
    Universite de Nantes, INSERM U539, CHU Hotel Dieu, Nantes, France
    Curr Opin Lipidol 18:304-9. 2007
  7. pmc The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro
    Fatiha Tabet
    Lipid Research Group, Heart Research Institute, Sydney, New South Wales, Australia
    Arterioscler Thromb Vasc Biol 30:246-52. 2010
  8. pmc The PCSK9 decade
    Gilles Lambert
    Laboratoire Inserm U957, Universite de Nantes, Faculte de Medecine, Nantes, France
    J Lipid Res 53:2515-24. 2012
  9. ncbi request reprint The differential apoA-I enrichment of prebeta1 and alphaHDL is detectable by gel filtration separation
    Maud Chetiveaux
    INSERM U539, Centre de Recherche en Nutrition Humaine, CHU Hotel Dieu, Nantes, France
    J Lipid Res 43:1986-93. 2002
  10. ncbi request reprint Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity
    Grace L Guo
    Laboratory of Metabolism, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 278:45062-71. 2003

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c
    Philippe Costet
    INSERM, U539, CHU Hotel Dieu, 44000, Nantes, France
    J Biol Chem 281:6211-8. 2006
    ..Together, these results show that PCSK9 expression is regulated by nutritional status and insulinemia...
  2. ncbi request reprint Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects
    Gilles Lambert
    Faculte de Medecine, Universite de Nantes, UMR Phan 1280, Nantes, France Lipid Research Group, Heart Research Institute, Sydney, Australia Electronic address
    J Am Coll Cardiol 63:2365-73. 2014
    ..convertase subtilisin/kexin type 9 (PCSK9) levels constitute an even greater risk for patients who already have reduced low-density lipoprotein receptor (LDLR) levels, such as those with heterozygous familial hypercholesterolemia (HeFH)?..
  3. ncbi request reprint Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor
    Gilles Lambert
    Universite de Nantes, UFR de Medecine, Institut National de la Sante et de la Recherche Medicale, Unité 539, Centre Hospitalier Universitaire Hotel Dieu, 44093 Nantes, France
    Endocrinology 147:4985-95. 2006
    ..In summary, the negative modulation of LDLr expression by PCSK9, which decreases plasma LDL clearance, also promotes an overproduction of nascent VLDL in vivo upon fasting...
  4. ncbi request reprint PCSK9: a promising therapeutic target for dyslipidemias?
    Gilles Lambert
    University of Nantes, Medical School, INSERM U539, CHU Hotel Dieu, 3 e Nord, 1 Place Alexis Ricordeau, F 44093 Nantes cedex 1, France
    Trends Endocrinol Metab 17:79-81. 2006
    ..humans, the characterization of PCSK9-deficient mice hypersensitive to statins and the severely pathological phenotype of D374Y PCSK9-mutated patients shed a new light on this gene: is it a promising therapeutic target for dyslipidemias?..
  5. ncbi request reprint Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells
    Florent Lalanne
    Institut National de la Santé et de la Recherche Médicale U539, Centre Hospitalier Universitaire, Hotel Dieu, Nantes, France
    J Lipid Res 46:1312-9. 2005
    ..Finally, we show that unlike PCSK9 overexpression in mice, the S127R mutation in patients led to increased VLDL apoB levels, suggesting a potential gain of function for S127R-PCSK9 in humans...
  6. ncbi request reprint Unravelling the functional significance of PCSK9
    Gilles Lambert
    Universite de Nantes, INSERM U539, CHU Hotel Dieu, Nantes, France
    Curr Opin Lipidol 18:304-9. 2007
    ..This review summarizes recent studies published in print or online before January 2007 which have investigated the functional significance of this intriguing protease...
  7. pmc The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro
    Fatiha Tabet
    Lipid Research Group, Heart Research Institute, Sydney, New South Wales, Australia
    Arterioscler Thromb Vasc Biol 30:246-52. 2010
    ..The effects of the 5A/PLPC complex were no longer apparent in HCAECs knocked down for ABCA1...
  8. pmc The PCSK9 decade
    Gilles Lambert
    Laboratoire Inserm U957, Universite de Nantes, Faculte de Medecine, Nantes, France
    J Lipid Res 53:2515-24. 2012
    ..Initial data from investigations of PCSK9 inhibition in humans are promising and indicate that PCSK9 inhibition may be a viable new therapeutic option for the treatment of dyslipidemia and associated cardiovascular diseases...
  9. ncbi request reprint The differential apoA-I enrichment of prebeta1 and alphaHDL is detectable by gel filtration separation
    Maud Chetiveaux
    INSERM U539, Centre de Recherche en Nutrition Humaine, CHU Hotel Dieu, Nantes, France
    J Lipid Res 43:1986-93. 2002
    ..This original and new method should help to understand the kinetics of HDL in humans and the reverse cholesterol transport dynamics...
  10. ncbi request reprint Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity
    Grace L Guo
    Laboratory of Metabolism, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 278:45062-71. 2003
    ..Furthermore, FXR, PXR, and CAR protect against hepatic bile acid toxicity in a complementary manner, suggesting that they serve as redundant but distinct layers of defense to prevent overt hepatic damage by bile acids during cholestasis...
  11. ncbi request reprint The farnesoid X-receptor is an essential regulator of cholesterol homeostasis
    Gilles Lambert
    Molecular Disease Branch, NHLBI, National Institutes of Health NIH, Bethesda, Maryland 20892, USA
    J Biol Chem 278:2563-70. 2003
    ..These data demonstrate that FXR is a critical regulator of normal cholesterol metabolism and that genetic changes affecting FXR function have the potential to be pro-atherogenic...
  12. ncbi request reprint Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice
    Elyisha A Hanniman
    Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada
    J Lipid Res 46:2595-604. 2005
    ..In conclusion, loss of FXR function is associated with decreased survival, increased severity of defects in lipid metabolism, and more extensive aortic plaque formation in a mouse model of atherosclerotic disease...
  13. pmc Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes
    Kimihiko Matsusue
    Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Frederick, Maryland 20892, USA
    J Clin Invest 111:737-47. 2003
    ..These data indicate that hepatic PPARgamma plays a critical role in the regulation of TG content and in the homeostasis of blood glucose and insulin resistance in steatotic diabetic mice...
  14. ncbi request reprint [PCSK9: a new gene involved in familial hypercholesteremia]
    Gilles Lambert
    Med Sci (Paris) 20:1068-70. 2004
  15. ncbi request reprint Hepatic CCAAT/enhancer binding protein alpha mediates induction of lipogenesis and regulation of glucose homeostasis in leptin-deficient mice
    Kimihiko Matsusue
    Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Endocrinol 18:2751-64. 2004
    ..Taken together, these results indicate that hepatic C/EBP alpha plays a critical role in the acceleration of lipogenesis in ob/ob mice and in glucose homeostasis by the indirect regulation of insulin secretion...
  16. ncbi request reprint Disruption of hepatic C/EBPalpha results in impaired glucose tolerance and age-dependent hepatosteatosis
    Yusuke Inoue
    Laboratory of Metabolism, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 279:44740-8. 2004
    ..These data demonstrate that hepatic C/EBPalpha is critical for ammonia detoxification and glucose and lipid homeostasis in adult mice...
  17. ncbi request reprint Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet
    Taro E Akiyama
    Laboratory of Metabolism, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Building 37, Bethesda, MD 20892, USA
    J Biol Chem 279:20874-81. 2004
    ....
  18. ncbi request reprint Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
    Vivienne M Homer
    Canterbury Health Laboratories, 8001 Christchurch, New Zealand
    Atherosclerosis 196:659-66. 2008
    ..Our study therefore indicates that PCSK9 mediated inhibition of the LDLR does not require PCSK9 autocatalytic cleavage or secretion, suggesting that PCSK9 may also function intracellularly...
  19. doi request reprint Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment
    Gilles Lambert
    The Heart Research Institute, Sydney, Australia
    Clin Chem 54:1038-45. 2008
    ..Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the LDL receptor (LDLr) in hepatocytes, and its expression in mouse liver has been shown to decrease with fenofibrate treatment...
  20. pmc Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease
    Sung Hoon Ahn
    Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Inflamm Bowel Dis 14:908-20. 2008
    ..While HNF4alpha expression is critical for liver function, its role in the gut and in the pathogenesis of inflammatory bowel disease (IBD) is unknown...
  21. pmc Disruption of the Arnt gene in endothelial cells causes hepatic vascular defects and partial embryonic lethality in mice
    Sun Hee Yim
    Laboratory of Metabolism, National Cancer Institute, Bethesda, MD 20892, USA
    Hepatology 44:550-60. 2006
    ..Adult ArntDeltaEC mice carrying embryonic hepatic defects developed what was possibly an early stage of cirrhosis with consequences of limited oxygen availability and altered lipid metabolism...
  22. ncbi request reprint Apolipoprotein A-IV is regulated by nutritional and metabolic stress: involvement of glucocorticoids, HNF-4 alpha, and PGC-1 alpha
    Elyhisha A Hanniman
    Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada
    J Lipid Res 47:2503-14. 2006
    ..Together, these results indicate that the induction of apoA-IV expression in fasting and diabetes likely involves PGC-1 alpha-mediated coactivation of HNF-4 alpha in addition to glucocorticoid-dependent actions...
  23. pmc Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux
    Taro E Akiyama
    Laboratory of Metabolism, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Cell Biol 22:2607-19. 2002
    ..Together, these data indicate that PPAR gamma plays a critical role in the regulation of cholesterol homeostasis by controlling the expression of a network of genes that mediate cholesterol efflux from cells and its transport in plasma...
  24. pmc The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice
    Charles W Joyce
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 99:407-12. 2002
    ....